Bayer BAYRY announced that the FDA has accepted its new drug application (NDA) for its investigational, once-daily, oral ...

Asundexian plus antiplatelet therapy reduces IS risk in patients with noncardioembolic stroke or high-risk transient ischemic attack.

A stroke can happen suddenly and without warning, but health experts say the body often sends critical signals that should ...

Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) ...

A "mini stroke" or TIA is a warning sign that a full stroke may be imminent. Learn the symptoms and what to do, according to Fairfield Medical Center.

Results from the OCEANIC-STROKE trial show that the investigational Factor XIa inhibitor, asundexian, not only reduces the ...

US FDA & Japan’s MHLW accept Bayer’s FXIa inhibitor, asundexian for prevention of ischemic stroke: Berlin Wednesday, May 20, 2026, 12:00 Hrs [IST] Bayer announced that the US ...

Speakers warn that transient neurologic events may conceal high-risk vascular disease, seizures, or amnestic syndromes ...

Thanks to the prestigious prevention grant from the Swedish Heart Lung Foundation, he will further develop a mobile app ...

In the phase 3 OCEANIC-STROKE trial, asundexian significantly reduced recurrent ischemic stroke risk compared with placebo without significantly increasing major bleeding. The Food and Drug ...